We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

GAUZ:NASDAQGauzy Ltd. Analysis

Data as of 2026-04-05 - not real-time

$0.76

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Gauzy Ltd. is trading at a fraction of its historical valuation with a price-to-sales multiple that is exceptionally low, reflecting a market that has heavily discounted its distressed financial profile. The company reports negative margins across the board, a substantial debt load, and cash balances that are insufficient to cover its obligations, while revenue is contracting. Technically, the stock sits below its short‑ and medium‑term moving averages, the broader trend is bearish, and volume has been waning, all of which underscore continued downward pressure. However, the MACD has turned mildly bullish and forward earnings estimates suggest a potential earnings rebound, creating a narrow window for upside if the business can stabilize.
Recent corporate actions, including the addition of an experienced director to the board and a successful effort to regain Nasdaq compliance, signal an intent to address governance and liquidity concerns, yet the company also received a notice regarding its minimum bid price, highlighting ongoing compliance risk. Given the extreme price volatility, high beta, and sector exposure to cyclical technology demand, investors face a blend of valuation appeal and substantial downside risk, making the stock a highly speculative play.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 7/10

Key Factors

  • severe earnings and cash deficits
  • persistent bearish technical positioning
  • Nasdaq minimum price compliance uncertainty

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • potential earnings improvement in forward outlook
  • board reinforcement and governance upgrades
  • still elevated debt and liquidity constraints

Long Term

> 3 years
Positive
Model confidence: 4/10

Key Factors

  • deep valuation discount relative to industry peers
  • possible restructuring or asset monetization
  • high volatility offering upside if turnaround succeeds

Key Metrics & Analysis

Financial Health

Revenue Growth-17.80%
Profit Margin-39.63%
P/E Ratio1.3
ROE-94.46%
ROA-13.03%
Debt/Equity354.31
P/B Ratio0.8
Op. Cash Flow$-20112000
Free Cash Flow$-10643000
Industry P/E33.5

Technical Analysis

TrendBearish
RSI55.0
Support$0.47
Resistance$1.00
MA 20$0.66
MA 50$0.73
MA 200$3.83
MACDBullish
VolumeDecreasing
Fear & Greed Index78.8

Valuation

GradeUndervalued
TypeValue

Risk Assessment

Beta1.00
Volatility133.22%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.